Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This study is designed to investigate whether the sodium-glucose co-transporter-2 (SGLT-2)
inhibitor Empagliflozin reduces sympathetic nervous system (SNS) activity in humans.